Abstracts Archive - Page 2032 of 2425 - ACR Meeting Abstracts

Abstract Number: 286 • 2014 ACR/ARHP Annual Meeting
Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study
Katherine Green¹, Marinka Twilt² and Taunton R. Southwood³, ¹Rheumatology, Birmingham Children's Hospital, Birmingham, United Kingdom, ²Paediatrics, Aarhus University Hospital, Aarhus, Denmark, ³Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom
Background/Purpose The 2011 ACR recommendations for the treatment of Juvenile Idiopathic Arthritis (ACR-JIA) are evidence-based, consensus-approved therapeutic pathways for the safe and effective treatment of…
Abstract Number: 285 • 2014 ACR/ARHP Annual Meeting
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Gerd Horneff¹, Hans Huppertz², Gerd Ganser³, Johannes Peter Haas⁴, Ivan Foeldvari⁵ and Kirsten Minden⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²Prof Hess Children’s Hospital, Bremen, Germany, ³Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁴German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶Epidemiology unit, German Rheumatism Research Center, Berlin, Germany
Background/Purpose Drug surveillance of biologics in juvenile patients using registries is of immense importance as patient numbers and duration in clinical trials are limited. There…
Abstract Number: 284 • 2014 ACR/ARHP Annual Meeting
Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)– Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis
S.J. Vastert¹, Victor Boom², Jordi Anton³, Tamás Constantin⁴, Pavla Dolezalova⁵, Gerd Horneff⁶, Pekka Lahdenne⁷, Bo Magnusson⁸, Kirsten Minden⁹, K. Nistala¹⁰, Pierre Quartier¹¹, Ingrida Rumba-Rozenfelde¹², Nicolino Ruperto¹³, Vanessa Remy Piccolo¹⁴, Ricardo A. G. Russo¹⁵, Yosef Uziel¹⁶, Carine Wouters¹⁷, Alberto Martini¹⁸, Angelo Ravelli¹⁹, Helen Foster²⁰ and Nico Wulffraat²¹, ¹Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁵Paediatric Rheumatiology unit, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic, ⁶Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁷Paediatrics, Helsinki University Central Hospital, Helsinki, Finland, ⁸Pediatric Rheumatology, Astrid Lindgren Children's Hospital, Stockholm, Sweden, ⁹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹²University of Latvia, Riga, Latvia, ¹³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ¹⁴Pediatric Rheumatology, Hopital Necker Enfants Malades, Paris, France, ¹⁵Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁶Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ¹⁷University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹University of Genova, Genova, Italy, ²⁰Newcastle University, Newcastle, United Kingdom, ²¹Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic pediatric rheumatic diseases (PRD). As is the case for most PRD's, evidence-based guidelines…
Abstract Number: 283 • 2014 ACR/ARHP Annual Meeting
Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis
Lauren Minor¹, Keith Sikora², April D. Brundidge³, Robert A. Colbert⁴ and Hemalatha Srinivasalu⁵, ¹NIAMS, NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, DC, ³NIAMS NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, MD, ⁵Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: Enthesitis is a characteristic feature of spondyloarthritis (SpA). Clinical evaluation of enthesitis by palpation is subject to differences in pressure used at different sites…
Abstract Number: 282 • 2014 ACR/ARHP Annual Meeting
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Joost F. Swart¹, Alessandro Consolaro², Gerd Horneff³, Kimme L. Hyrich⁴, Francesca Bovis⁵, Bo Magnusson⁶, Jose Melo-Gomes⁷, Ekaterina Alexeeva⁸, Stefano Lanni⁹, Gerd Ganser¹⁰, Violeta Vladislava Panaviene¹¹, Jordi Anton¹², Ivan Foeldvari¹³, Valda Stanevicha¹⁴, Susan Nielsen¹⁵, Ralf Trauzeddel¹⁶, Constantin Ailioaie¹⁷, Pierre Quartier¹⁸, Toni Hospach¹⁹, Gordana Susic²⁰, Maria Trachana²¹, Frank Weller-Heinemann²², Alberto Martini²³, Nico Wulffraat²⁴ and Nicolino Ruperto²⁵, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵Pediatria II, PRINTO, PRINTO - Istituto Giannina Gaslini, Genoa, Italy, ⁶Pediatric Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁷Pediatric Rheumatology, Lisbon, Portugal, ⁸Scientific Centre of Children’s Health of RAMS, Moscow, Russia, ⁹Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ¹⁰Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ¹¹Children‘s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ¹²Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ¹⁴Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹⁵University Clinic of Pediatrics II, Rigshospitalet, Copenhagen, Denmark, ¹⁶Pediatrics, Helios Clinics, Berlin, Germany, ¹⁷Department of Medical Physics, Alexandru Ioan Cuza University, Iasi, Romania, ¹⁸Necker-Enfants Malades Hospital, Paris, France, ¹⁹Pediatric Rheumatology, Olgahospital, Stuttgart, Germany, ²⁰Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Serbia, ²¹Aristotle University, Thessaloniki, Greece, ²²Klinikum Bremen-Mitte, Bremen, Germany, ²³PRINTO-IRCCS, Genova, Italy, ²⁴Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁵Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). However,…
Abstract Number: 281 • 2014 ACR/ARHP Annual Meeting
Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections
Elaine Ramsay¹, Heather Benham², Jenna Tress³, Janille Diaz⁴ and David D. Sherry³, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Texas Scottish Rite Hospital for Children, Dallas, TX, ³Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia,, PA
Background/Purpose Intraarticular corticosteroid injection (IACI) is one of the most common treatment modalities in oligoarticular Juvenile Idiopathic Arthritis (JIA). There is widespread use of IACI…
Abstract Number: 280 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Katerina Jarosova¹, Karel Hejduk², Michal Uher² and Jiri Vencovsky, MD, DSc³, ¹clinical, Institution of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic
Background/Purpose To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA).Methods ATTRA is the Czech national registry of…
Abstract Number: 279 • 2014 ACR/ARHP Annual Meeting
Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care
Alysha Taxter¹, Keshia Maughn², Edward M. Behrens³ and Pamela F. Weiss⁴, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose National registry cross-sectional data show significant differences in patient-reported outcomes (PROs) across juvenile idiopathic arthritis (JIA) subtypes. This study aimed to assess predictors of…
Abstract Number: 278 • 2014 ACR/ARHP Annual Meeting
Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis?
Alessandro Consolaro¹, Maddalena Allegra², Maria C. Gallo¹, Benedetta Schiappapietra², Serena Calandra¹, Cristina Robbiano², Federica Mongelli³, Cecilia Bava³, Alberto Martini^2,3 and Angelo Ravelli^4,5, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³University of Genova, Genova, Italy, ⁴Istituto Gaslini-PRINTO, Genova, Italy, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose Morning stiffness is a major symptom of juvenile idiopathic arthritis (JIA) and it is usually associated with active disease. However, it is common view…
Abstract Number: 297 • 2014 ACR/ARHP Annual Meeting
S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
Alexandra R Aminoff¹, Carol A Wallace¹, Sarah Ringold², Anne Stevens³ and Jessica M Foster⁴, ¹Pediatric Rheumatology, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ³Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose There is a lack of reliable biomarkers that correlate with active juvenile idiopathic arthritis (JIA). The S100A8/A9 heterodimer (calprotectin) and S100A12 are proinflammatory…
Abstract Number: 296 • 2014 ACR/ARHP Annual Meeting
Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect
Andrea Scheuern¹, Nadine Fischer², Johannes-Peter Haas¹ and Boris Hugle¹, ¹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²Research, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Background/Purpose: Methotrexate (MTX) is the mainstay treatment in the therapy of children with juvenile idiopathic arthritis (JIA) and can lead to prolonged remission and improved…
Abstract Number: 295 • 2014 ACR/ARHP Annual Meeting
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Eileen Baildam¹, Roberto Carrasco², Susannah Holt³, Helen Foster⁴, Lucy R. Wedderburn⁵, Alice Chieng⁶, Joyce Davidson⁷, Yiannis Ioannou⁸, Kimme L. Hyrich⁹ and Wendy Thomson¹⁰, ¹Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Paediatric Palliative Care, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Newcastle University Medical School, Professor of Paediatric Rheumatology, Newcastle Upon Tyne, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁶Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁷Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁸Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁰Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Intra-articular corticosteroid injections (IACI) are a standard treatment in juvenile idiopathic arthritis (JIA). This study assessed response to IACI in a large prospective cohort…
Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 292 • 2014 ACR/ARHP Annual Meeting
Flares in Children with JIA: Results from the Reacch-out Cohort
Lori B. Tucker¹, Jaime Guzman¹, Kiem Oen² and ReACCh Out Investigators³, ¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ³BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Disease flares are a concern to patients with JIA, their parents, and caregivers alike; but little is known of disease manifestations during a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].